🇪🇺 Briviact in European Union

EMA authorised Briviact on 13 January 2016

Marketing authorisations

EMA — authorised 13 January 2016

  • Application: EMEA/H/C/003898
  • Marketing authorisation holder: UCB Pharma SA
  • Local brand name: Briviact (in Italy: Nubriveo)
  • Indication: Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
  • Status: approved

Read official source →

EMA — authorised 14 January 2016

  • Marketing authorisation holder: UCB Pharma SA
  • Status: approved

Briviact in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in European Union

Frequently asked questions

Is Briviact approved in European Union?

Yes. EMA authorised it on 13 January 2016; EMA authorised it on 14 January 2016.

Who is the marketing authorisation holder for Briviact in European Union?

UCB Pharma SA holds the EU marketing authorisation.